Related Experiment Video
Updated: Jul 18, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke
1Department of Neurology, The Adelaide and Meath Hospital Tallaght, Trinity College Dublin, Dublin 24, Republic of Ireland. dominick.mccabe@amnch.ie
Insights
Warfarin is the preferred anticoagulant for preventing secondary strokes in patients with atrial fibrillation or flutter. Aspirin is a less effective alternative when warfarin is contraindicated, and anticoagulation is considered for left ventricular thrombus.
Area of Science:
- Cardiology
- Neurology
- Vascular Medicine
Background:
- Transient ischaemic attack (TIA) and ischaemic stroke patients often have underlying conditions like atrial fibrillation, flutter, or cardiac abnormalities.
- Effective secondary stroke prevention strategies are crucial for these high-risk patient groups.
Purpose of the Study:
- To review anti-thrombotic and interventional therapies for TIA or ischaemic stroke in patients with specific cardiac conditions.
- To provide guidance on the optimal use of anticoagulation and antiplatelet therapies.
Main Methods:
- Review of peer-reviewed data on anti-thrombotic and interventional therapies.
- Analysis of treatment strategies for non-valvular atrial fibrillation, atrial flutter, interatrial septal abnormalities, and left ventricular thrombus.
Main Results:
- Long-term warfarin therapy is recommended for secondary stroke prevention in non-valvular atrial fibrillation/flutter.
- Aspirin is a less effective alternative when warfarin is contraindicated.
- Anticoagulation is considered for TIA/stroke associated with left ventricular thrombus.
Conclusions:
- Warfarin, targeting an international normalised ratio of 2-3, offers the best balance for secondary stroke prevention.
- Management of TIA/stroke in young patients with interatrial septal defects requires further research and clinical trials.
- Empirical anticoagulation is a reasonable consideration for specific cases of TIA/stroke with left ventricular thrombus.
Abstract:
Peer-reviewed data pertaining to anti-thrombotic and interventional therapy for transient ischaemic attack (TIA) or ischaemic stroke patients with non-valvular atrial fibrillation, atrial flutter, interatrial septal abnormalities, or left ventricular thrombus were reviewed. Long-term oral anticoagulant therapy with warfarin is the treatment of choice for secondary stroke prevention following TIA or minor ischaemic stroke in association with persistent or paroxysmal non-valvular atrial fibrillation or atrial flutter. If warfarin is contraindicated, long-term aspirin is a safe, but much less effective alternative treatment option in this subgroup of patients with cerebrovascular disease. Management of young patients with TIA or stroke in association with an interatrial septal defect is controversial. Various treatment options are outlined, but readers are encouraged to include these patients in one of the ongoing randomised clinical trials in this area. It is reasonable to consider empirical anticoagulation in patients with TIA or ischaemic stroke in association with left ventricular thrombus formation following myocardial infarction or in association with idiopathic dilated cardiomyopathy. If warfarin is prescribed, one should aim for a target international normalised ratio of 2.5 (range 2-3) to achieve the best balance between adequate secondary prevention of cardioembolic events and the risk of major haemorrhagic complications.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Transient Ischemic Attack l: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Ischemic Stroke l: Introduction
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
